Chemoimmunotherapy Vs Standard Care in ESCC: Is One Better?

Neoadjuvant chemoimmunotherapy is associated with significantly improved survival outcomes compared with standard chemoradiotherapy in patients with locally advanced ESCC.
Medscape Medical News

source https://www.medscape.com/viewarticle/chemoimmunotherapy-vs-standard-chemoradiotherapy-escc-one-2025a100076g?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost